Current oncology (Toronto, Ont.)HumansAntibodiesMonoclonalHumanizedFemale
Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review.
Khashayar Yazdanpanah Ardakani, Gaia Passarella, Andrea Gerardo Antonio Lania, Thoma Dario Clementi, Alessandro Fanti, Francesca Fulvia Pepe, Serena Capici, Marina Elena Cazzaniga
Published: 202610.3390/curroncol33010028
Abstract
Pembrolizumab, an anti-PD-1 monoclonal antibody, showed promising results in the treatment of different types of solid tumors and generally an improvement in overall survival and patients' outcome. However, as a drug that targets the immune system to…
Preview only. Read the full abstract at the source